Building Efficiency into Biologics Formulations Development

Efficient Biologics Production

FDA’s Quality Management Maturity Program:
Why should CDMOs adhere to the new CDER’s Rating System?

Bispecific antibodies unleashed

Lyophilization: Protecting and preserving biologics

Rapid discovery and characterization of monoclonal antibodies against the SARS-CoV-2 Delta spike protein

The value of engaging a single CDMO for comprehensive biologics services from discovery to GMP manufacturing

The current and future value of mRNA vaccines and therapeutics

Leveraging efficiency from cell line development to clinical manufacturing of monoclonal antibodies

Leveraging the immunological diversity of the PentaMice® platform for COVID-19 antibody discovery

Antibody-based drug discovery at the speed of light

The benefits of end-to-end formulation and fill-finish of biologics